{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Two generic versions of ADHD medication Concerta remain on market despite evidence that they are inferior; Food and Drug Administration reported that generics were less effective than Concerta and gave Mallinckrodt Pharmaceuticals and UCB six months to prove otherwise, deadline that has since lapsed with neither company announcing plans to withdraw the drugs.", "type_of_material": "News", "word_count": "1102", "lead_paragraph": "The F.D.A. says that two generic versions of Concerta, an extended-release form of Ritalin for A.D.H.D., don\u2019t measure up to the brand drug. But both are still on the market.", "pub_date": "2015-06-17T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Generic A.D.H.D. Drug, Not Equivalent to the Brand, Is in Use Anyway", "print_headline": "Generic Drug, Found Flawed, Is Still in Use "}, "snippet": "The F.D.A. says that two generic versions of Concerta, an extended-release form of Ritalin for A.D.H.D., don\u2019t measure up to the brand drug. But both are still on the market.", "multimedia": [{"height": 126, "url": "images/2015/06/17/business/17CONCERTA/17CONCERTA-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/06/17/business/17CONCERTA/17CONCERTA-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/06/17/business/17CONCERTA/17CONCERTA-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/06/17/business/17CONCERTA/17CONCERTA-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/06/17/business/17CONCERTA/17CONCERTA-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/06/17/business/17CONCERTA/17CONCERTA-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/06/17/business/generic-ritalin-drug-not-equivalent-to-the-brand-is-in-use-anyway.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Generic Brands and Products", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "UCB SA", "name": "organizations"}, {"rank": "5", "is_major": "Y", "value": "Mallinckrodt Pharmaceuticals", "name": "organizations"}, {"rank": "6", "is_major": "Y", "value": "Attention Deficit Hyperactivity Disorder", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Ritalin (Drug)", "name": "subject"}], "blog": [], "_id": "558092fb38f0d81a60726e5b", "source": "The New York Times"}